ATE262327T1 - Verwendung von verbindungen zur erhöhung der pyruvatdehydrogenaseaktivität - Google Patents

Verwendung von verbindungen zur erhöhung der pyruvatdehydrogenaseaktivität

Info

Publication number
ATE262327T1
ATE262327T1 AT99923767T AT99923767T ATE262327T1 AT E262327 T1 ATE262327 T1 AT E262327T1 AT 99923767 T AT99923767 T AT 99923767T AT 99923767 T AT99923767 T AT 99923767T AT E262327 T1 ATE262327 T1 AT E262327T1
Authority
AT
Austria
Prior art keywords
sup
compounds
formula
dehydrogenase activity
pyruvate dehydrogenase
Prior art date
Application number
AT99923767T
Other languages
English (en)
Inventor
Roger John Butlin
Thorsten Nowak
Jeremy Nicholas Burrows
Michael Howard Block
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE262327T1 publication Critical patent/ATE262327T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT99923767T 1998-05-29 1999-05-26 Verwendung von verbindungen zur erhöhung der pyruvatdehydrogenaseaktivität ATE262327T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9811427.5A GB9811427D0 (en) 1998-05-29 1998-05-29 Chemical compounds
PCT/GB1999/001669 WO1999062506A1 (en) 1998-05-29 1999-05-26 Use of compounds for the elevation of pyruvate dehydrogenase activity

Publications (1)

Publication Number Publication Date
ATE262327T1 true ATE262327T1 (de) 2004-04-15

Family

ID=10832817

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923767T ATE262327T1 (de) 1998-05-29 1999-05-26 Verwendung von verbindungen zur erhöhung der pyruvatdehydrogenaseaktivität

Country Status (30)

Country Link
US (2) US6498275B1 (de)
EP (1) EP1082110B1 (de)
JP (2) JP3857051B2 (de)
KR (1) KR100638685B1 (de)
CN (2) CN1303281A (de)
AT (1) ATE262327T1 (de)
AU (1) AU740909B2 (de)
BR (1) BR9910821A (de)
CA (1) CA2331685C (de)
CZ (1) CZ300240B6 (de)
DE (1) DE69915823T2 (de)
DK (1) DK1082110T3 (de)
EE (1) EE04738B1 (de)
ES (1) ES2217754T3 (de)
GB (2) GB9811427D0 (de)
HU (1) HUP0103721A3 (de)
ID (1) ID27531A (de)
IL (2) IL139996A0 (de)
IS (1) IS2074B (de)
MY (1) MY125815A (de)
NO (1) NO20006010L (de)
NZ (1) NZ507784A (de)
PL (1) PL198505B1 (de)
PT (1) PT1082110E (de)
RU (1) RU2242224C2 (de)
SK (1) SK285862B6 (de)
TR (1) TR200003524T2 (de)
TW (1) TWI237563B (de)
WO (1) WO1999062506A1 (de)
ZA (1) ZA200006645B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
MY122278A (en) 1999-07-19 2006-04-29 Upjohn Co 1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
US7030109B2 (en) 1999-07-19 2006-04-18 Pharmacia & Upjohn Company 1,2,3,4,5,6-Hexahydroazepino[4,5-b]indoles containing arylsulfones at the 9-position
WO2001017956A1 (en) * 1999-09-04 2001-03-15 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
US6552225B1 (en) 1999-09-04 2003-04-22 Astrazeneca Ab Chemical compounds
JP2003508509A (ja) 1999-09-04 2003-03-04 アストラゼネカ アクチボラグ ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
GB0012012D0 (en) * 2000-05-19 2000-07-05 Astrazeneca Ab Chemical compound
NZ523656A (en) * 2000-08-31 2004-11-26 Pfizer Prod Inc Pyrazole derivatives and their use as protein kinase inhibitors
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
GB0120471D0 (en) * 2001-08-23 2001-10-17 Astrazeneca Ab Chemical compounds
US7161031B2 (en) * 2002-02-28 2007-01-09 Temple University - Of The Commonwealth System Of Higher Education Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
US7115644B2 (en) 2002-09-13 2006-10-03 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds
EP1613303A1 (de) * 2003-03-21 2006-01-11 H. Lundbeck A/S Substituierte p-diaminobenzol-derivate
WO2005092040A2 (en) * 2004-03-22 2005-10-06 The Regents Of The University Of California A formulation for increasing endogenous adiponectin and leptin production
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
JP2006347936A (ja) * 2005-06-15 2006-12-28 Bayer Cropscience Ag 殺虫性ベンズアニリド類
MX2010002193A (es) * 2007-09-07 2010-03-18 Ge Healthcare Ltd Metodo de determinacion de actividad pdh y generacion de imagen para su uso en dicho metodo.
CA2758071C (en) 2009-04-06 2018-01-09 Agios Pharmaceuticals, Inc. Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
SG10201403696UA (en) 2009-06-29 2014-10-30 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
FR2950889B1 (fr) * 2009-10-06 2011-11-18 Tetrahedron Procede de synthese de l'ergothioneine et analogues
WO2012088314A1 (en) 2010-12-21 2012-06-28 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
JP6272754B2 (ja) 2011-05-03 2018-01-31 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼ活性化剤の使用方法
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
CN103951584B (zh) * 2014-03-11 2016-02-10 清华大学 3-氯-n-苯基-4-(3,3,3-三氟-2-甲基-2-羟基丙酰胺基)苯甲酰胺的衍生物及其制备方法与应用
CN104557697A (zh) * 2015-02-12 2015-04-29 佛山市赛维斯医药科技有限公司 含烷氧基取代的喹啉结构的葡萄糖激酶活化剂及其用途
CN104610143A (zh) * 2015-02-12 2015-05-13 佛山市赛维斯医药科技有限公司 一种含硝基喹啉结构的葡萄糖激酶活化剂及其用途
CN104592113A (zh) * 2015-02-12 2015-05-06 佛山市赛维斯医药科技有限公司 含喹啉和腈基苯结构的葡萄糖激酶活化剂及用途
CN106831567A (zh) * 2015-02-12 2017-06-13 佛山市赛维斯医药科技有限公司 含卤代喹啉结构的葡萄糖激酶活化剂、制备方法及其用途
CN104557700A (zh) * 2015-02-12 2015-04-29 佛山市赛维斯医药科技有限公司 一种含腈基喹啉结构的葡萄糖激酶活化剂及其用途
CN104592112A (zh) * 2015-02-12 2015-05-06 佛山市赛维斯医药科技有限公司 一类含喹啉和硝基苯结构的葡萄糖激酶活化剂及用途
CN104557695A (zh) * 2015-02-12 2015-04-29 佛山市赛维斯医药科技有限公司 含喹啉结构的葡萄糖激酶活化剂、制备方法及其用途
CN104557698A (zh) * 2015-02-12 2015-04-29 佛山市赛维斯医药科技有限公司 含喹啉基和烷氧苯基结构的葡萄糖激酶活化剂及用途
RS64777B1 (sr) 2015-06-11 2023-11-30 Agios Pharmaceuticals Inc Postupci upotrebe aktivatora piruvat kinaze

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2862100D1 (en) 1977-10-12 1983-01-05 Ici Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
AU8961382A (en) 1981-11-06 1983-05-12 Imperial Chemical Industries Plc Amide derivatives
US4537618A (en) 1982-05-26 1985-08-27 Ciba Geigy Corporation N-phenylsulfonyl-N'-pyrimidinylureas
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8617652D0 (en) 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
GB8617653D0 (en) 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB9116069D0 (en) * 1991-07-25 1991-09-11 Ici Plc Therapeutic amides
GB9214120D0 (en) 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
EP0539329A1 (de) 1991-10-25 1993-04-28 Ciba-Geigy Ag Acetylen-Verbindungen, verwendbar als Leukotrien-Antagonisten
SE9103397D0 (sv) 1991-11-18 1991-11-18 Kabi Pharmacia Ab Nya substituerade salicylsyror
IL105558A (en) 1992-05-18 1998-04-05 Zeneca Ltd Tertiary carbinols having potassium channel activity, process for their preparation and pharmaceutical compositions containing them
GB9305295D0 (en) * 1993-03-15 1993-05-05 Zeneca Ltd Therapeutic compounds
GB9309716D0 (en) * 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
GB9310069D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Heterocyclic compounds
GB9310095D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
GB2278054A (en) 1993-05-18 1994-11-23 Zeneca Ltd Compounds for the treatment of urinary incontinence
GB9505082D0 (en) * 1995-03-14 1995-05-03 Zeneca Ltd Medicament
GB9607458D0 (en) 1996-04-10 1996-06-12 Zeneca Ltd Enzymatic process for stereoselective preparation of therapeutic amides
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
GB9811932D0 (en) 1998-06-04 1998-07-29 Zeneca Ltd Chemical compunds

Also Published As

Publication number Publication date
ZA200006645B (en) 2002-08-15
GB9811427D0 (en) 1998-07-22
IS2074B (is) 2005-12-15
EP1082110A1 (de) 2001-03-14
CA2331685C (en) 2008-12-23
SK285862B6 (sk) 2007-10-04
RU2242224C2 (ru) 2004-12-20
AU740909B2 (en) 2001-11-15
JP3857051B2 (ja) 2006-12-13
IL139996A (en) 2006-07-05
WO1999062506A1 (en) 1999-12-09
IL139996A0 (en) 2002-02-10
EP1082110B1 (de) 2004-03-24
NO20006010D0 (no) 2000-11-28
ID27531A (id) 2001-04-12
JP2002516854A (ja) 2002-06-11
DE69915823D1 (de) 2004-04-29
CN1303281A (zh) 2001-07-11
CZ20004424A3 (cs) 2001-03-14
DK1082110T3 (da) 2004-07-05
DE69915823T2 (de) 2005-03-24
SK18002000A3 (sk) 2001-05-10
US20040009979A1 (en) 2004-01-15
CA2331685A1 (en) 1999-12-09
EE200000691A (et) 2002-04-15
HUP0103721A3 (en) 2002-12-28
NO20006010L (no) 2001-01-26
PT1082110E (pt) 2004-07-30
PL198505B1 (pl) 2008-06-30
CZ300240B6 (cs) 2009-03-25
GB9911762D0 (en) 1999-07-21
PL344447A1 (en) 2001-11-05
ES2217754T3 (es) 2004-11-01
BR9910821A (pt) 2001-02-13
TWI237563B (en) 2005-08-11
KR100638685B1 (ko) 2006-10-27
TR200003524T2 (tr) 2001-10-22
CN101417964A (zh) 2009-04-29
KR20010043898A (ko) 2001-05-25
IS5717A (is) 2000-11-17
US6960688B2 (en) 2005-11-01
AU4052499A (en) 1999-12-20
US6498275B1 (en) 2002-12-24
JP2006306884A (ja) 2006-11-09
MY125815A (en) 2006-08-30
HUP0103721A2 (en) 2002-06-29
NZ507784A (en) 2002-10-25
HK1033652A1 (en) 2001-09-14
EE04738B1 (et) 2006-12-15

Similar Documents

Publication Publication Date Title
DE69915823D1 (de) Verwendung von verbindungen zur erhöhung der pyruvatdehydrogenaseaktivität
ATE399753T1 (de) Amide als pyruvatdehydrogenaseinhibitoren
AU6294298A (en) Matrix metalloproteinase inhibitors
AU2736088A (en) Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
CA2336412A1 (en) Medicament for treatment of diabetes
NO154089C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
AU3262599A (en) Chemical compounds and their use to elevate pyruvate dehydrogenase activity
BG106520A (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
AU6853700A (en) Chemical compounds
EP1156057A4 (de) Malto-oligosaccharid-derivate und ihre anwendungen
AU7152094A (en) New 2(1H)-quinolone compounds, process for their preparationand the pharmaceutical compositions which contain them
EA200000374A2 (ru) Новые соединения 2,3-метаноаминокислоты, способ их получения и содержащие их фармацевтические композиции
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
ES543781A0 (es) Procedimiento de preparacion de un derivado 1,1-difenilpro- pan-1-ol
ATE259802T1 (de) Verbindungen mit antithrombotischer wirkung
ES2133095A1 (es) Acidos alquilidenglutaminicos con propiedades farmaceuticas.
IT1312319B1 (it) Procedimento per la preparazione del citalopram.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1082110

Country of ref document: EP

REN Ceased due to non-payment of the annual fee